ClinicalTrials.gg
CompletedNCT04134767Updated Dec 21, 2023Results posted

Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)

An interventional study of Health Linkage and Overdose Education in Substance Use, HIV Infections and HCV Infection, sponsored by April M Young. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-21.

Primary conditionDrug OverdoseRegistry: Substance-Related DisordersReclassifiedWhy we changed it
Registry
Substance-Related Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Drug Overdose
Why
  1. The study's listed conditions name Drug Overdose, a narrower term within Substance-Related Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by April M Young · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Drug Overdose with a site in United States — 17 open to participants now, 28 under way, none of them phase 3. Drug Overdose · United States.

Enrollment
28th of 58
234 · median 182
Started
2019
with 9 others
No phase
51 of 72
13 open now
Registered
32nd of 72
by date
Lead sponsor
2 of 72
April M Young

Among the 72 studies in Drug Overdose with a site in United States, this one is the 28th largest by enrollment of the 58 interventional ones that give a count, is one of 10 that started in 2019, is one of 51 with no phase, and was the 32nd registered.

Drug Overdose

104 studies on the registry are indexed under Drug Overdose; 22 are open to participants now.

Browse Drug Overdose studies →

Open to participants now

17 of the 72 studies in Drug Overdose with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Drug Overdose studies recruiting now, 12 (92%) set no upper age limit and 1 (8%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Drug Overdose with a site in United States, or all of them as a file.
02

Study summary

This study will test the effects of an intervention to reduce substance use and related harms among people leaving rural jails or otherwise involved in the criminal justice system. This study will compare people in a health linkage intervention with people who will get overdose (OD) education. Everyone will take part in the baseline and follow-up surveys and receive OD education. Participants will be assigned to one of the two groups by chance based on when they are enrolled to the study and if their county is randomly assigned to an intervention or a comparison condition. By doing this study, the investigators hope to learn if providing linkage to health services along with HIV, hepatitis C virus (HCV), and overdose education to people leaving rural jails or otherwise involved in the criminal justice system will reduce substance use and related harms.

Read the detailed description

The overarching objective of this study is to determine the effectiveness of an evidence-based community response project using a community randomized trial. Specifically, the investigators will test the effect of an intervention to reduce substance use and related harms among people re- entering the community from rural jails or otherwise recently involved in the criminal justice system (out on bond, under warrant for arrest, arrested, on pre-trial supervision, probation or parole, court-involved, or under home incarceration with digital monitoring). This study will compare people in a health navigation intervention with a comparison group of people who will get overdose education. Everyone will take part in follow-up surveys for up to 6 months after release. The intervention is a health navigation intervention designed to reduce substance use disorder (SUD) and increase engagement in the SUD care cascade; reduce vulnerability to HIV, sexually transmitted infections (STIs), and HCV and increase engagement in the HIV, STI, and HCV care cascades; and reduce vulnerability to overdose deaths among adults who use drugs and are leaving local jails or otherwise involved in the criminal justice system. The intervention is based on enhancements to START, a Center for Disease Control-recognized, evidence-based, individual-level intervention designed to reduce HIV/STI/HCV risk.

START core components: (1) Hold pre- and post-release program sessions with clients transitioning back to the community from a correctional setting; (2) Use a client-focused incremental risk reduction approach; (3) Use assessment \& documentation tools to provide structure; (4) Hire program staff that are familiar with HIV/STIs/HCV prevention and with the specific needs of people being released; (5) Staff /client relationships must be maintained post-release; (6) Conduct enrollment and schedule two pre-release program sessions within 60 days of a client's release that: a. give HIV/STI/HCV information; b. review client's HIV/STI/HCV risk; c. identify transitional needs; d. develop a personalized risk reduction and transitional plan; e. make facilitated referrals; 7) Schedule four post-release sessions to review and update the risk reduction/ transitional plan(s) and provide facilitated referrals; (8) Provide condoms at each post-release session; (9) Actively maintain contact with clients.

The investigators will modify START a priori as follows: 1) Though originally designed for young men, START has been successfully applied to women leaving correctional settings. The investigators will implement START with all genders; 2) START originally targeted incarcerated people preparing to leave correction facilities. The investigators will continue to target individuals who are incarcerated but also expand the target population to people who are involved in other parts of the criminal justice system (e.g., those out on bond, under warrant for arrest, arrested, court-involved; those on probation, parole or pre-trial supervision; and individuals under home incarceration with digital monitoring [an ankle monitoring program]). Individuals who are not incarcerated will be recruited in the communities. 3) All intervention sessions will be conducted in the community setting (post-release for those recruited in jails). 4) START's post-release sessions primarily occurred in homes and community venues, such as restaurants. Staff who will deliver START will be stationed primarily within the local department of health (DOH); 5) To enhance START's impact on drug use and HIV/HCV-related harms (e.g., drug injection frequency), the investigators will integrate the NIDA (National Institute on Drug Abuse) Standard HIV intervention into START, including rapid HIV and HCV antibody testing and counseling. In addition, START interventionists will distribute harm reduction supplies at the first intervention session with people who inject drugs (PWID). The NIDA Standard has been demonstrated to reduce drug use frequency, high-risk injection practices, and sexual risk; 6) START was not designed to reduce overdoses. The investigators will integrate an interactive training with animated scenarios and narration on preventing, recognizing, and responding effectively to an opioid OD. Participants in the intervention group will receive naloxone (not all participants will get naloxone), at their first intervention session. Interventionists will encompass OD in risk reduction motivational interviewing. 7) To accommodate participants who are not able to visit the study office in-person, data collection and intervention sessions will be conducted remotely via phone or videoconferencing.

CARE2HOPE covers the following counties: Rowan, Bath, Morgan, Menifee, Elliott, Lee, Owsley, Wolfe, Perry, Letcher, Leslie, Knott. Research staff will recruit participants from a) jails, b) Probation, Parole and Pre-Trial Services c) digital jails (i.e. home incarceration with digital monitoring programs); d) peer referral; e) existing participants in CARE2HOPE and other University of Kentucky studies, including PROUD-R2 (Peer-Based Retention of People Who Use Drugs in Rural Research) and SNAP (Social Networks among Appalachian People), who have consented to be contacted to learn about future studies; f) harm reduction and social service programs serving people who use drugs; and g) community-based organizations serving the 12 CARE2HOPE counties. Recruitment in jails will involve jails either located in CARE2HOPE counties or counties that have contracts with them to incarcerate their residents. The intervention sessions and data collection will be delivered by research staff called "Rural Health Navigators" or "REHNs". Participants are assigned to one of the two groups by chance based on when they are enrolled to the study and when their county is randomly chosen to start the project. Counties were originally randomized using a stepped wedge design. The counties were then randomized in November 2020, accounting for a new study design. The investigators randomized 12 study counties to two groups. In Months 1-6 six counties randomly assigned to Group 1 will recruit participants to the intervention, while in the remaining six counties (Group 2) the participants will be enrolled into a control condition. The investigators anticipate an average enrollment of 40 participants per county per arm, with a total final sample size for the trial of 960 (n=480intervention, n=480comparison). After a county has met its target enrollment in both conditions, the intervention and comparison activities will no longer be offered in that county.

Originally, the CARE2HOPE trial gathered data in three waves: at baseline, before the intervention had been delivered in the intervention counties; at three months post baseline, just after the intervention had been completed; and at six months post baseline, to support analyses of intervention decay. On June 24th 2022, the CARE2HOPE Data Safety Monitoring Board (DSMB) met to determine whether the trial could limit data collection to two waves - baseline and the 3-month follow up - and still ethically meet its aims. The DSMB voted to drop the six-month wave of data collection recognizing that:

  1. Ending data collection at 3 months permitted the trial to test intervention effectiveness, given that the intervention itself lasted \<3 months.
  2. The shortened follow-up period allowed the trial to continue to enroll new participants for an additional 3 months, thus increasing capacity to generate a sufficient sample size to power analyses.
03

Conditions studied

  • Substance Use
  • HIV Infections
  • HCV Infection
  • Sexually Transmitted Infections (Not HIV or Hepatitis)
  • Overdose, Drug
  • Opioid Use
04

In context

Drug Overdose Reclassified

104 studies on the registry are indexed under Drug Overdose; 22 are open to participants now.

This study's enrollment of 234 is above the median of 124 across 76 interventional studies indexed under Drug Overdose.

Browse Drug Overdose studies →

Lead sponsor

April M Young is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Drug Overdose, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Substance-Related Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be aged 18 or older; and
  • A resident of one of the 12 CARE2HOPE (C2H) counties randomized to intervention or control data collection; and
  • Have used opioids to get high in the past 30 days or have injected any drug to get high during that same period (if incarcerated at home under digital monitoring program or on probation or parole: have used opioids to get high or injected any drug to get high in 30 days before the date of incarceration or start of the probation or parole term); and
  • Have been recently involved in the criminal justice system defined as being incarcerated in jail or prison, out on bond, under warrant for arrest, arrested, under pre-trial supervision, on probation or parole, court-involved, or individuals who are incarcerated at home under an electronic monitoring program (i.e., digital jail) in the past 30 days.

OR

  • Be a resident of or anticipate being released to one of the 12 CARE2HOPE counties randomized to intervention or control data collection; and
  • Have used opioids to get high in the 30 days before they were incarcerated, or have injected any drug to get high during that period; and
  • Be aged 18 or older; and
  • Be incarcerated in a local jail and expected to be released in \<21 days

OR

  • Be a participant in the CARE2HOPE longitudinal survey who consented to be contacted for future research; and
  • Be a resident of or anticipate being released to one of the 12 CARE2HOPE counties randomized to intervention or control data collection; and
  • Have used opioids to get high in the 30 days before they were incarcerated, or have injected any drug to get high during that period; and
  • Be aged 18 or older; and
  • Be incarcerated in a local jail and expected to be released in \<21 days

Exclusion criteria

Exclusion criteria:

  1. Previously enrolled in the START-C2H study (i.e., cannot enroll more than once)
  2. Not speaking English fluently
  3. Residence in or move to a county not randomized to intervention or control data collection within 21 days of release
  4. Transfer to prison
  5. Being charged with a violent crime (e.g., homicide, murder, rape and sexual assault, robbery, and assault)
  6. Having been incarcerated for one year or more
06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    Health Linkage

    Research staff will: 1) meet with participants in person or virtually to ask questions about drug use and related behaviors, service access, and personal goals; provide overdose education and help develop a plan for reducing risks and accessing services; conduct drug testing, offer HIV and HCV testing and counseling, naloxone, and harm reduction supplies, and connection with needed services; 2) follow up with participants monthly for three months to help overcome challenges; and 3) six months post-enrollment, contact participants to conduct drug testing. Participants will complete surveys at baseline, 3 months, and 6 months

    Behavioral: Health Linkage · Behavioral: Overdose Education

  • Other
    Overdose Education

    The investigators will initiate the comparison group in Group 2 counties six months before the intervention begins. Research staff will conduct an overdose intervention with the comparison cohort. This will occur pre-release if individual is recruited in jail. The comparison group participants will watch a video on preventing, recognizing, and responding effectively to an opioid OD, accompanied by information about Kentucky's Good Samaritan Law and Naloxone Access Law. Research staff will answer questions after the video. Individuals will receive a Community Resource Guide at this visit. As in the intervention group, the comparison group participants will complete surveys at the baseline (in jail if recruited in jail, in a community setting if recruited in the community), and at 3 months and 6 months after the baseline. Surveys will be identical to those delivered to the intervention cohort.

    Behavioral: Overdose Education

Interventions

  • BehavioralHealth Linkage

    Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.

  • BehavioralOverdose Education

    Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.

07

What researchers measure

Primary outcomes

  1. Change in Substance Use Frequency

    Item:Self-reported frequency of substance use to get high in past 30 days (continuous variable) Source: Rural opioid initiative (ROI Harmonized UG3 Survey) Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

Secondary outcomes

  1. Change in Engagement in HIV Risk Behaviors - Receptive Syringe Sharing

    Item: Self-reported recent (past 30 days) frequency of engaging in the HIV risk behavior of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  2. Change in Engagement in HIV Risk Behaviors - Condomless Sex

    Item: Self-reported recent (past 30 days) frequency of condomless anal or vaginal sex (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  3. Change in Engagement in HCV Risk Behaviors - Receptive Syringe Sharing

    Item: Self-reported recent (past 30 days) frequency of engaging in the hepatitis C risk behavior of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  4. Change in Engagement in HCV Risk Behaviors - Shared Injection Equipment

    Item: Self-reported recent (past 30 days) frequency of shared cookers, cotton, spoon, or water (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  5. Change in Frequency of Opioid Overdose

    Item:Self-reported recent (past 90 days) number of times overdosed (ordinal, continuous) Source: Modified from ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  6. Change in Frequency of Receptive Syringe Sharing

    Item:Self-reported recent (past 30 days) frequency of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  7. Change in Frequency of Injection Drug Use

    Item: Self-reported recent (past 30 days) frequency of injection (ordinal, continuous) Source: ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  8. Change in Number of Days Carrying Naloxone

    Item:Self-reported recent (past 90 days) number of days carrying naloxone (continuous) Source: Modified from ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  9. Change in Evidence-based Responses to a Witnessed Overdose

    Item: Self-reported recent (past 90 days) engagement in evidence-based responses (i.e., called 911, gave naloxone, stayed until an ambulance or police arrived, transported person to the hospital) to a witnessed overdose by self or other bystanders (nominal) Source: CDC NHBS Supplemental overdose items

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  10. Change in Number of Days on Medication for Opioid Use Disorder (MOUD) Among Participants for Whom MOUD is Indicated

    Item:Self-reported recent (past 90 days) frequency of being on MOUD (continuous) Source: Modified from ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  11. Change in Linkage to Follow-up HCV Testing Among Those Who Test HCV Antibody Positive

    Item:Self-reported recent (past 90 days) access to follow-up HCV RNA testing (nominal); (among participants that had been told ever infected with HCV at baseline - our HCV testing item is not specific to RNA testing, ALL reporting HCV diagnosis at baseline were tested at baseline) Source: ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  12. Change in Linkage to Treatment Among Those Who Test HCV RNA Positive

    Item: Self-reported recent (past 90 days) frequency of receiving treatment among those who test RNA positive (binary) Source: Modified from ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

  13. Change in Proportion of Syringes Obtained From Syringe Service Program Among Participants Who Inject Drugs

    Item: Self-reported proportion of recent (past 90 days) injections that involved a new, sterile syringe obtained from a syringe service program (continuous, proportion) Source: ROI Harmonized UG3 Survey

    Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported

08

Results

Posted Dec 21, 2023
Limitations and caveats
Because of the impact of the COVID-19 pandemic, we were unable to accrue the target number of participants in either the intervention counties or the comparison counties. As a result, analyses of intervention effectiveness are underpowered. Further, data related to the follow-up HCV testing outcome should be interpreted with caution; measuring RNA-based follow-up testing for HCV is too nuanced to capture via a survey item, as it can be easily misinterpreted by participants.

Participant flow

Participant flow — Overall Study
MilestoneHealth LinkageOverdose Education
Started111123
Completed6781
Not completed4442
Withdrew: Death01
Withdrew: Removed for harassing staff01
Withdrew: Lost to follow-up4440

Outcome measures

PrimaryChange in Substance Use Frequency

Item:Self-reported frequency of substance use to get high in past 30 days (continuous variable) Source: Rural opioid initiative (ROI Harmonized UG3 Survey) Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Days of drug use
Change in Substance Use Frequency
Days of drug useHealth LinkageOverdose Education
Change in Substance Use Frequency-11.2 (-14.8 to -7.7)-5.5 (-8.4 to -2.6)
SecondaryChange in Engagement in HIV Risk Behaviors - Receptive Syringe Sharing

Item: Self-reported recent (past 30 days) frequency of engaging in the HIV risk behavior of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Receptive syringe shares
Change in Engagement in HIV Risk Behaviors - Receptive Syringe Sharing
Receptive syringe sharesHealth LinkageOverdose Education
Change in Engagement in HIV Risk Behaviors - Receptive Syringe Sharing-4.0 (-9.0 to 1.0)5.1 (-7.0 to 17.3)
SecondaryChange in Engagement in HIV Risk Behaviors - Condomless Sex

Item: Self-reported recent (past 30 days) frequency of condomless anal or vaginal sex (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Number of times had condomless sex
Change in Engagement in HIV Risk Behaviors - Condomless Sex
Number of times had condomless sexHealth LinkageOverdose Education
all participants-0.7 (-3.9 to 2.5)-1.7 (-4.6 to 1.3)
participants with > 1 sex partner-0.4 (-4.0 to 3.2)-2.0 (-5.9 to 1.8)
SecondaryChange in Engagement in HCV Risk Behaviors - Receptive Syringe Sharing

Item: Self-reported recent (past 30 days) frequency of engaging in the hepatitis C risk behavior of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Receptive syringe shares
Change in Engagement in HCV Risk Behaviors - Receptive Syringe Sharing
Receptive syringe sharesHealth LinkageOverdose Education
Change in Engagement in HCV Risk Behaviors - Receptive Syringe Sharing-4.0 (-9.0 to 1.0)5.1 (-7.0 to 17.3)
SecondaryChange in Engagement in HCV Risk Behaviors - Shared Injection Equipment

Item: Self-reported recent (past 30 days) frequency of shared cookers, cotton, spoon, or water (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Number of times shared equipment
Change in Engagement in HCV Risk Behaviors - Shared Injection Equipment
Number of times shared equipmentHealth LinkageOverdose Education
Change in Engagement in HCV Risk Behaviors - Shared Injection Equipment-10.6 (-18.2 to -3.0)4.5 (-7.7 to 16.8)
SecondaryChange in Frequency of Opioid Overdose

Item:Self-reported recent (past 90 days) number of times overdosed (ordinal, continuous) Source: Modified from ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Number of times overdosed
Change in Frequency of Opioid Overdose
Number of times overdosedHealth LinkageOverdose Education
Change in Frequency of Opioid Overdose-0.25 (-0.6 to 0.10)-0.59 (-1.2 to 0.02)
SecondaryChange in Frequency of Receptive Syringe Sharing

Item:Self-reported recent (past 30 days) frequency of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Receptive syringe shares
Change in Frequency of Receptive Syringe Sharing
Receptive syringe sharesHealth LinkageOverdose Education
Change in Frequency of Receptive Syringe Sharing-4.0 (-9.0 to 1.0)5.1 (-7.0 to 17.3)
SecondaryChange in Frequency of Injection Drug Use

Item: Self-reported recent (past 30 days) frequency of injection (ordinal, continuous) Source: ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Number of times injected drugs
Change in Frequency of Injection Drug Use
Number of times injected drugsHealth LinkageOverdose Education
Change in Frequency of Injection Drug Use-33.7 (-49.2 to -18.3)-19.5 (-30.2 to -8.7)
SecondaryChange in Number of Days Carrying Naloxone

Item:Self-reported recent (past 90 days) number of days carrying naloxone (continuous) Source: Modified from ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Number of days carrying naloxone
Change in Number of Days Carrying Naloxone
Number of days carrying naloxoneHealth LinkageOverdose Education
Change in Number of Days Carrying Naloxone4.5 (-8.5 to 17.5)0 (-9.7 to 9.7)
SecondaryChange in Evidence-based Responses to a Witnessed Overdose

Item: Self-reported recent (past 90 days) engagement in evidence-based responses (i.e., called 911, gave naloxone, stayed until an ambulance or police arrived, transported person to the hospital) to a witnessed overdose by self or other bystanders (nominal) Source: CDC NHBS Supplemental overdose items

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Evidence-based responses to overdose
Change in Evidence-based Responses to a Witnessed Overdose
Evidence-based responses to overdoseHealth LinkageOverdose Education
Change in Evidence-based Responses to a Witnessed Overdose0.1 (-0.9 to 1.1)-0.2 (-0.6 to 0.1)
SecondaryChange in Number of Days on Medication for Opioid Use Disorder (MOUD) Among Participants for Whom MOUD is Indicated

Item:Self-reported recent (past 90 days) frequency of being on MOUD (continuous) Source: Modified from ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Days on MOUD
Change in Number of Days on Medication for Opioid Use Disorder (MOUD) Among Participants for Whom MOUD is Indicated
Days on MOUDHealth LinkageOverdose Education
Change in Number of Days on Medication for Opioid Use Disorder (MOUD) Among Participants for Whom MOUD is Indicated23.5 (-0.4 to 47.3)8.2 (-7.1 to 23.6)
SecondaryChange in Linkage to Follow-up HCV Testing Among Those Who Test HCV Antibody Positive

Item:Self-reported recent (past 90 days) access to follow-up HCV RNA testing (nominal); (among participants that had been told ever infected with HCV at baseline - our HCV testing item is not specific to RNA testing, ALL reporting HCV diagnosis at baseline were tested at baseline) Source: ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Number · Percent with follow-up HCV test
Change in Linkage to Follow-up HCV Testing Among Those Who Test HCV Antibody Positive
Percent with follow-up HCV testHealth LinkageOverdose Education
Change in Linkage to Follow-up HCV Testing Among Those Who Test HCV Antibody Positive-40-33.3
SecondaryChange in Linkage to Treatment Among Those Who Test HCV RNA Positive

Item: Self-reported recent (past 90 days) frequency of receiving treatment among those who test RNA positive (binary) Source: Modified from ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Number · Percent linked to treatment
Change in Linkage to Treatment Among Those Who Test HCV RNA Positive
Percent linked to treatmentHealth LinkageOverdose Education
Change in Linkage to Treatment Among Those Who Test HCV RNA Positive0-5.9
SecondaryChange in Proportion of Syringes Obtained From Syringe Service Program Among Participants Who Inject Drugs

Item: Self-reported proportion of recent (past 90 days) injections that involved a new, sterile syringe obtained from a syringe service program (continuous, proportion) Source: ROI Harmonized UG3 Survey

Time frame:
assessed at 3 months and 6 months after the baseline, change at 3 months reported
Reported as:
Mean · Percentage of syringes obtained at SSP
Change in Proportion of Syringes Obtained From Syringe Service Program Among Participants Who Inject Drugs
Percentage of syringes obtained at SSPHealth LinkageOverdose Education
Change in Proportion of Syringes Obtained From Syringe Service Program Among Participants Who Inject Drugs12.4 (-10.9 to 35.7)0 (-11.2 to 11.2)

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Health Linkage0/111 (0%)10/111 (9%)5/111 (4.5%)
Overdose Education1/123 (0.8%)12/123 (9.8%)27/123 (22%)
Most frequent serious events
Most frequent serious events
EventHealth LinkageOverdose Education
Non Fatal OverdoseGeneral disorders7/1117/123
Emergency Room visit or HospitalizationGeneral disorders3/1114/123
DeathGeneral disorders0/1111/123
Most frequent other events
Most frequent other events
EventHealth LinkageOverdose Education
Infected with hepatitis CInfections and infestations5/11124/123
Believed correctional officers could hear interviewGeneral disorders0/1111/123
problems with family members, friends, or partners and infected with hepatitis CSocial circumstances0/1111/123
Believed correctional officers could hear interview and infected with hepatitis CGeneral disorders0/1111/123

Baseline characteristics

One participant from the Health Linkage Arm did not have demographic data available

Age, Continuous
Age, Continuous(years)Health LinkageOverdose EducationTotal
Mean37.2 ± 8.438.4 ± 7.137.8 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)Health LinkageOverdose EducationTotal
Female5863121
Male5260112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Health LinkageOverdose EducationTotal
Hispanic or Latino202
Not Hispanic or Latino107122229
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Health LinkageOverdose EducationTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White106120226
More than one race022
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(participants)Health LinkageOverdose EducationTotal
United States110123233
09

Study locations

1 site
  • University of Kentucky
    Lexington, Kentucky 40506, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from the University of Kentucky are required to be submitted to the University of Washington as part of the NIH-funded Rural Opioid Initiative (ROI) data harmonization project. The University of Washington Data Harmonization Coordinating Center (DCC) will be harmonizing data across 8 ROI studies in order to create new, harmonized datasets to be used for analyses across the consortium. The University of Washington and other ROI grantees will perform data analyses on these data for peer-reviewed publication. The harmonized datasets will be provided to other ROI grantees as required for analysis and will be considered under the umbrella of mandated DCC activities. No third parties outside of the ROI will be given access to this harmonized data. Harmonized datasets will be built to specific project concept proposals, and all project proposals must be reviewed and approved by the ROI consortium's Publications Working Group before distribution of the customized dataset.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Oct 2022, 35 months.

Results were first posted in Dec 2023, 1 year 1 month after primary completion.

Of 47 non-industry interventional studies with no phase under Drug Overdose, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's 35 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 13 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 22, 2019
StartActual
Nov 15, 2019
Primary completionActual
Oct 27, 2022
CompletionActual
Oct 27, 2022
Results first posted
Dec 21, 2023
Last update
Dec 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04134767
Lead sponsor
April M Young
Collaborators
National Institute on Drug Abuse (NIDA), Appalachian Regional Commission, Substance Abuse and Mental Health Services Administration (SAMHSA), Centers for Disease Control and Prevention, Emory University
Responsible party
April M Young (Associate Professor, Department of Epidemiology, University of Kentucky) — Sponsor-investigator
First posted
Oct 22, 2019
Start date
Nov 15, 2019
Primary completion
Oct 27, 2022
Completion
Oct 27, 2022
Results posted
Dec 21, 2023
Last update
Dec 21, 2023

Study contacts

April M Young, PhD, MPH
principal investigator · University of Kentucky

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion